Invacare 2014 Annual Report Download - page 19

I-15
FORWARD-LOOKING INFORMATION
This Form 10-K contains forward-looking statements within the meaning of the “Safe Harbor” provisions of the Private
Securities Litigation Reform Act of 1995. Terms such as “will,” “should,” “could,” “plan,” “intend,” “expect,” “continue,”
“believe” and “anticipate,” as well as similar comments, denote forward-looking statements that are subject to inherent
uncertainties that are difficult to predict. Actual results and events may differ significantly from those expressed or anticipated as
a result of risks and uncertainties, which include, but are not limited to, the following: legal actions, including adverse judgments
or settlements of litigation or claims in excess of available insurance limits; regulatory proceedings or the Company's failure to
comply with regulatory requirements or receive regulatory clearance or approval for the Company's products or operations in
the United States or abroad; adverse effects of regulatory or governmental inspections of Company facilities and governmental
enforcement actions; product liability or warranty claims; product recalls, including more extensive recall experience than
expected; compliance costs, limitations on the production and/or distribution of the Company's products, inability to bid on or
win certain contracts, unabsorbed capacity utilization, including fixed costs and overhead, or other adverse effects of the FDA
consent decree of injunction; any circumstances or developments that might further delay or adversely impact the results of the
final, most comprehensive third-party expert certification audit or FDA inspection of the Company's quality systems at the Elyria,
Ohio, facilities impacted by the FDA consent decree, including any possible requirement to perform additional remediation
activities or further resultant delays in receipt of the written notification to resume operations (which could have a material adverse
effect on the Company's business, financial condition, liquidity or results of operations); the failure or refusal of customers or
healthcare professionals to sign verification of medical necessity (VMN) documentation or other certification forms required by
the exceptions to the FDA consent decree; possible adverse effects of being leveraged, including interest rate or event of default
risks; the Company's inability to satisfy its liquidity needs in light of monthly borrowing base movements and daily cash needs of
the business under its new asset-based lending credit facility; adverse changes in government and other third-party payor
reimbursement levels and practices both in the U.S. and in other countries (such as, for example, more extensive pre-payment
reviews and post-payment audits by payors, or the Medicare National Competitive Bidding program); impacts of the U.S. Affordable
Care Act of 2010 (such as, for example, the impact on the Company of the excise tax on certain medical devices, and the Company's
ability to successfully offset such impact); ineffective cost reduction and restructuring efforts or inability to realize anticipated
cost savings or achieve desired efficiencies from such efforts; delays, disruptions or excessive costs incurred in facility closures
or consolidations; exchange rate or tax rate fluctuations; inability to design, manufacture, distribute and achieve market acceptance
of new products with greater functionality or lower costs or new product platforms that deliver the anticipated benefits;
consolidation of health care providers; lower cost imports; uncollectible accounts receivable; difficulties in implementing/
upgrading Enterprise Resource Planning systems; risks inherent in managing and operating businesses in many different foreign
jurisdictions; decreased availability or increased costs of materials which could increase the Company's costs of producing or
acquiring the Company's products, including possible increases in commodity costs or freight costs; heightened vulnerability to
a hostile takeover attempt arising from depressed market prices for Company shares; provisions of Ohio law or in the Company's
debt agreements, shareholder rights plan or charter documents that may prevent or delay a change in control, as well as the risks
described from time to time in the Company's reports as filed with the Securities and Exchange Commission. Except to the extent
required by law, the Company does not undertake and specifically declines any obligation to review or update any forward-looking
statements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments
or otherwise.